Grifols, S.A. (GIKLY) Stock

About Grifols, S.A.

Grifols, S.A. is a company dedicated to the acquisition, production, processing, and distribution of therapeutic goods, with a primary focus on plasma-derived medicines. Its operations are structured across several key divisions: Bioscience, Hospital, Diagnostic, Bio Supplies, and other segments. The Bioscience unit is responsible for researching, developing, manufacturing, and marketing plasma-based medications and other cutting-edge treatments. These solutions address chronic, rare, widespread, and life-threatening conditions. Its extensive product line includes immunoglobulins, alpha-1 antitrypsin, albumin, various clotting factors, and hyperimmune globulins. Through its Hospital division, Grifols provides non-biological pharmaceuticals and a range of medical supplies, such as items for clinical nutrition, intravenous treatment, and diverse medical devices. The Diagnostic division concentrates on the research, development, production, and commercialization of diagnostic tools for healthcare professionals. These products encompass the entire patient care journey, from initial prevention and screening to diagnosis, prognosis, and the ongoing monitoring of diseases and treatments. Furthermore, the Bio Supplies division furnishes biological components essential for life-science research, clinical investigations, and the manufacturing of both pharmaceutical and diagnostic products. Healthcare providers globally rely on Grifols' offerings to diagnose and manage a variety of conditions, including hemophilia, immune system disorders, infectious diseases, and numerous other health issues. Its broad client base spans both public and private entities, encompassing wholesalers, distributors, collective purchasing groups, blood banks, hospitals, various care facilities, and national healthcare systems. Grifols, S.A. also maintains a technological partnership with Mondragon. Established in 1940, the company's corporate headquarters are situated in Barcelona, Spain.

Grifols, S.A. is headquartered in ES.

Grifols, S.A. (GIKLY) stock trades at $5.10 with a market capitalization of $13.40B. The stock is valued at a price-to-earnings (P/E) ratio of 14.79, price-to-book of 1.12, price-to-sales of 0.83. Over the past 52 weeks the stock has ranged between $5.06 and $7.49, and currently trades 31.9% below its 52-week high. It pays a dividend yielding 0.98%.

On profitability, Grifols, S.A. generates a return on equity (ROE) of 7.88%, return on capital employed of 7.00%, an operating margin of 16.89%, a net profit margin of 5.58%.

Official website: www.grifols.com